Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Hepatocellular 4Adenocarcinoma of Lung 2Recurrence 1Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder) 1Neoplasms 1Liver Neoplasms 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

Magnetic Resonance Spectroscopy 17Blood Specimen Collection 8Bevacizumab 8Temozolomide 7Radiotherapy 5Palliative Care 4Surgical Procedures, Operative 3Restraint, Physical 3Radiation 3Biopsy 3Yoga 2Standard of Care 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Psychosocial Intervention 2Perfusion Magnetic Resonance Imaging 2Mind-Body Therapies 2Magnetic Resonance Imaging 2Lomustine 2Gadolinium DTPA 2Elasticity Imaging Techniques 2Early Intervention, Educational 2Drug Therapy 2Diet Therapy 2Dexamethasone 2Chemotherapy, Adjuvant 2Aminolevulinic Acid 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Glioblastoma × tislelizumab × Clear all
NCT05811793 2023-04-13

Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.

Second Affiliated Hospital of Nanchang University

Phase NA Unknown
36 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡